Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | BTK | Q06187 | 9/20 | 0.49 |
| ▸ | ITK | Q08881 | 6/20 | 0.49 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24151443 | 1.00 | JAK3 (0.51) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL30190528 | 0.82 | JAK3 (0.58) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL24151660 | 0.82 | JAK3 (0.58) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL24150530 | 0.76 | MAP4K4 (0.60) | JAK3BTKJAK1EGFRERBB2 | |
| SCHEMBL24150841 | 0.75 | MAP4K4 (0.44) | JAK3BTKITKPIK3CD | |
| SCHEMBL24151089 | 0.75 | EGFR (0.62) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL30190618 | 0.75 | MAP4K4 (0.44) | JAK3BTKITKPIK3CD | |
| SCHEMBL19878073 | 0.74 | BTK (0.51) | JAK3BTKITKPLCG1EGFR | |
| SCHEMBL18117681 | 0.74 | EGFR (0.67) | JAK3BTKITKEGFR | |
| SCHEMBL24150540 | 0.73 | JAK3 (0.60) | JAK3BTKITKPLCG1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | JAK3 4427/4885BTK 4194/4885ITK 4359/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | JAK3 4427/4885BTK 4194/4885ITK 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.